[250 Pages Report] The nephrology and urology incontinence devices market is expected to record a CAGR of 4.1% during the forecast period, up from US$ 38 Billion in 2021 to reach a valuation of US$ 46.4 Billion by 2026.
| Report Attributes | Details |
|---|---|
| Estimated Base Year Value (2021) | US$ 38 Billion |
| Anticipated Forecast Value (2026) | US$ 46.4 Billion |
| Projected Growth Rate (2022 to 2032) | 4.1% CAGR |
Sales of nephrology and urology incontinence devices are expected to rise due to government measures to support R&D in the field.
For instance, during the virtual KidneyX Summit in July 2020, the United States Department of Health and Human Services (HHS) and the American Society of Nephrology (ASN) revealed the six winners of the US$ 3 million KidneyX: Redesign Dialysis Phase 2 competition.
In addition to this, demand for nephrology and urology incontinence devices has also increased due to the focused concentration on providing digital solutions during the Covid-19 pandemic.
The global nephrology and urology devices market is predicted to increase due to the increasing geriatric population.
The sales of nephrology and urology incontinence devices are projected to be hampered by high installation costs for equipment such as lithotripters and sophisticated machines and further projected to contribute to the growth of nephrology and urology incontinence devices market share.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Presently, the sales of nephrology and urology incontinent devices are primarily driven by the rising prevalence of chronic kidney disease (CKD), Benign Prostatic Hyperplasia (BPH) and End Stage Renal Disease (ESRD).
Growing awareness programs about these particular diseases and personal hygiene among patients will result in the increased demand for nephrology and urology incontinent devices in the forecast years.
Also, with the increase in healthcare expenditure and favorable reimbursement in the developed countries, the sales of nephrology and urology incontinent devices are expected to have a healthy growth.
Rising incidence rates and health consequences of urological disorders result in the growing demand for nephrology and urology incontinence devices treatments to manage them, boosting the sales of neurology and urology incontinence devices.
Principal Consultant
Depending on geographic regions, the nephrology and urology incontinence devices market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific, Japan, and Middle East & Africa.
North America and Europe are expected to capture the most significant sales of nephrology and urology incontinence devices, followed by Asia Pacific countries where the demand for nephrology and urology incontinence devices market is expected to grow due to increased awareness of personal hygiene and an increase in disposable income of middle-class consumers.
Some of the key participating players in the nephrology and urology incontinence devices market are Baxter International Inc., C. R. Bard, Inc, Coloplast UK Ltd., Unicharm Corporation., Kimberly-Clark Corporation, Hollister Inc., ConvaTec, B.Braun Melsungen AG, SCA (Svenska Cellulosa Aktiebolaget) and others.
Increased demand for nephrology and urology incontinence devices is predicted to rise due to a growing desire for minimally invasive and non-invasive treatment approaches.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Report Attributes | Details |
|---|---|
| Growth Rate | CAGR of 4.1% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2015 to 2020 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in USD Million, Volume in Kilotons and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Regions Covered | North America; Latin America; Europe; APAC; Middle East and Africa |
| Key Countries Profiled | USA, Canada, Mexico, Brazil, Germany, Italy, France, UK, Spain, China, India, Japan, Australia, South Korea, ASEAN, GCC, Israel, South Africa, Central Africa |
| Key Companies Profiled | Baxter International Inc.; C. R. Bard, Inc.; Coloplast UK Ltd.; Unicharm Corporation; Kimerly-Clark Corporation; Hollister Inc.; ConvaTec; B.Braun Melsungen AG; SCA (Svenska Cellulosa Aktiebolaget) |
| Customization Scope | Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. |
The nephrology and urology incontinence devices market are predicted to register a CAGR of 4.1% during the forecast period.
Key players holding substantial nephrology and urology incontinence devices market share includes Baxter International Inc., C. R. Bard, Inc, Coloplast UK Ltd., Unicharm Corporation., Kimerly-Clark Corporation, Hollister Inc., ConvaTec, B.Braun Melsungen AG, SCA (Svenska Cellulosa Aktiebolaget) and others.
As per the analysis, the nephrology and urology incontinence devices market share are likely to be US$ 46.4 Bn by 2026.
Demand for nephrology and urology incontinence devices market is likely to rise on the back of increasing due to the focused concentration on providing digital solutions during Covid-19 pandemic and the increasing geriatric population.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Nephrology and Urology Incontinence Devices Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Bn) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Bn) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Nephrology and Urology Incontinence Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Product Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Bn) Analysis By Product Type, 2017-2021
5.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Product Type, 2022-2032
5.3.1. Penile Compression Device
5.3.2. Pessary
5.3.3. Urethral Insert
5.3.4. Artificial Urinary Sphincter
5.3.5. Bladder Neck Support Device
5.3.6. Urine Seal
5.3.7. Absorbent Products
5.3.8. Catheters
5.4. Y-o-Y Growth Trend Analysis By Product Type, 2017-2021
5.5. Absolute $ Opportunity Analysis By Product Type, 2022-2032
Deep-dive segmentation will be available in the sample on request
6. Global Nephrology and Urology Incontinence Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Bn) Analysis By Type, 2017-2021
6.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Type, 2022-2032
6.3.1. Stress Incontinence
6.3.2. Urge incontinence
6.3.3. Overflow Incontinence
6.3.4. Functional Incontinence
6.3.5. Mixed Incontinence
6.4. Y-o-Y Growth Trend Analysis By Type, 2017-2021
6.5. Absolute $ Opportunity Analysis By Type, 2022-2032
Deep-dive segmentation will be available in the sample on request
7. Global Nephrology and Urology Incontinence Devices Market Analysis 2017-2021 and Forecast 2022-2032, By End User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Bn) Analysis By End User, 2017-2021
7.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By End User, 2022-2032
7.3.1. Hospitals
7.3.2. Specialty Clinics
7.3.3. Homecare Settings
7.3.4. Nursing Homes
7.4. Y-o-Y Growth Trend Analysis By End User, 2017-2021
7.5. Absolute $ Opportunity Analysis By End User, 2022-2032
Deep-dive segmentation will be available in the sample on request
8. Global Nephrology and Urology Incontinence Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Bn) Analysis By Region, 2017-2021
8.3. Current Market Size Value (US$ Bn) Analysis and Forecast By Region, 2022-2032
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. East Asia
8.3.5. South Asia & Pacific
8.3.6. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Nephrology and Urology Incontinence Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
9.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. U.K.
9.2.1.2. Canada
9.2.2. By Product Type
9.2.3. By Type
9.2.4. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Product Type
9.3.3. By Type
9.3.4. By End User
9.4. Key Takeaways
10. Latin America Nephrology and Urology Incontinence Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Product Type
10.2.3. By Type
10.2.4. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Product Type
10.3.3. By Type
10.3.4. By End User
10.4. Key Takeaways
11. Europe Nephrology and Urology Incontinence Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. U.K.
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Product Type
11.2.3. By Type
11.2.4. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Product Type
11.3.3. By Type
11.3.4. By End User
11.4. Key Takeaways
12. East Asia Nephrology and Urology Incontinence Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.2. By Product Type
12.2.3. By Type
12.2.4. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Product Type
12.3.3. By Type
12.3.4. By End User
12.4. Key Takeaways
13. South Asia & Pacific Nephrology and Urology Incontinence Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Country
13.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
13.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Thailand
13.2.1.3. Indonesia
13.2.1.4. Malaysia
13.2.1.5. Singapore
13.2.1.6. Australia
13.2.1.7. New Zealand
13.2.1.8. Rest of South Asia & Pacific
13.2.2. By Product Type
13.2.3. By Type
13.2.4. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Product Type
13.3.3. By Type
13.3.4. By End User
13.4. Key Takeaways
14. MEA Nephrology and Urology Incontinence Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Country
14.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
14.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Product Type
14.2.3. By Type
14.2.4. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Product Type
14.3.3. By Type
14.3.4. By End User
14.4. Key Takeaways
15. Key Countries Nephrology and Urology Incontinence Devices Market Analysis
15.1. U.K.
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2021
15.1.2.1. By Product Type
15.1.2.2. By Type
15.1.2.3. By End User
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2021
15.2.2.1. By Product Type
15.2.2.2. By Type
15.2.2.3. By End User
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2021
15.3.2.1. By Product Type
15.3.2.2. By Type
15.3.2.3. By End User
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2021
15.4.2.1. By Product Type
15.4.2.2. By Type
15.4.2.3. By End User
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2021
15.5.2.1. By Product Type
15.5.2.2. By Type
15.5.2.3. By End User
15.6. U.K.
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2021
15.6.2.1. By Product Type
15.6.2.2. By Type
15.6.2.3. By End User
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2021
15.7.2.1. By Product Type
15.7.2.2. By Type
15.7.2.3. By End User
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2021
15.8.2.1. By Product Type
15.8.2.2. By Type
15.8.2.3. By End User
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2021
15.9.2.1. By Product Type
15.9.2.2. By Type
15.9.2.3. By End User
15.10. China
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2021
15.10.2.1. By Product Type
15.10.2.2. By Type
15.10.2.3. By End User
15.11. Japan
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2021
15.11.2.1. By Product Type
15.11.2.2. By Type
15.11.2.3. By End User
15.12. South Korea
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2021
15.12.2.1. By Product Type
15.12.2.2. By Type
15.12.2.3. By End User
15.13. India
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2021
15.13.2.1. By Product Type
15.13.2.2. By Type
15.13.2.3. By End User
15.14. Thailand
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2021
15.14.2.1. By Product Type
15.14.2.2. By Type
15.14.2.3. By End User
15.15. Indonesia
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2021
15.15.2.1. By Product Type
15.15.2.2. By Type
15.15.2.3. By End User
15.16. Malaysia
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2021
15.16.2.1. By Product Type
15.16.2.2. By Type
15.16.2.3. By End User
15.17. Singapore
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2021
15.17.2.1. By Product Type
15.17.2.2. By Type
15.17.2.3. By End User
15.18. Australia
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2021
15.18.2.1. By Product Type
15.18.2.2. By Type
15.18.2.3. By End User
15.19. New Zealand
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2021
15.19.2.1. By Product Type
15.19.2.2. By Type
15.19.2.3. By End User
15.20. GCC Countries
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2021
15.20.2.1. By Product Type
15.20.2.2. By Type
15.20.2.3. By End User
15.21. South Africa
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2021
15.21.2.1. By Product Type
15.21.2.2. By Type
15.21.2.3. By End User
15.22. Israel
15.22.1. Pricing Analysis
15.22.2. Market Share Analysis, 2021
15.22.2.1. By Product Type
15.22.2.2. By Type
15.22.2.3. By End User
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Product Type
16.3.3. By Type
16.3.4. By End User
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Becton, Dickinson and Company
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. UROMED Kurt Drews KG
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. Stryker Corporation
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. B. Braun Melsungen AG
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Boston Scientific Corporation
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Cook Medical LLC
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. CooperSurgical, Inc.
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Medgyn Products, Inc.
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Bioderm Inc.
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Thomas Medical, Inc.
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
17.1.11. Essity Hygiene and Health AB
17.1.11.1. Overview
17.1.11.2. Product Portfolio
17.1.11.3. Profitability by Market Segments
17.1.11.4. Sales Footprint
17.1.11.5. Strategy Overview
17.1.11.5.1. Marketing Strategy
17.1.12. ZEPHYR SURGICAL IMPLANTS SÀRL
17.1.12.1. Overview
17.1.12.2. Product Portfolio
17.1.12.3. Profitability by Market Segments
17.1.12.4. Sales Footprint
17.1.12.5. Strategy Overview
17.1.12.5.1. Marketing Strategy
17.1.13. Coloplast Corp.
17.1.13.1. Overview
17.1.13.2. Product Portfolio
17.1.13.3. Profitability by Market Segments
17.1.13.4. Sales Footprint
17.1.13.5. Strategy Overview
17.1.13.5.1. Marketing Strategy
17.1.14. Femeda Ltd.
17.1.14.1. Overview
17.1.14.2. Product Portfolio
17.1.14.3. Profitability by Market Segments
17.1.14.4. Sales Footprint
17.1.14.5. Strategy Overview
17.1.14.5.1. Marketing Strategy
17.1.15. Domtar Corporation
17.1.15.1. Overview
17.1.15.2. Product Portfolio
17.1.15.3. Profitability by Market Segments
17.1.15.4. Sales Footprint
17.1.15.5. Strategy Overview
17.1.15.5.1. Marketing Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
Nephrology and Urology Incontinence Devices Market
